Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
50 /100
MEDIUM RISK
Score updated Aug 28, 2026

KYMR — Kymera Therapeutics, Inc. Dilution Risk Tracker

Track KYMR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track KYMR — Get alerts when the score changes →

As of August 28, 2026, Kymera Therapeutics, Inc. (KYMR) has a DilutionWatch DilutionScore of 50/100, rated MEDIUM dilution risk. Kymera Therapeutics, Inc. has a market capitalization of $6.70B, 83.15M shares outstanding, 262 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
26
💰 Cash Runway
85
📊 Float Risk
25
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

Watch
Minor dilution signals detected
model est. 17%
💰 Capital Raise model 35%
• Low cash runway: 6 months remaining
🔔 Track KYMR — Get forecast alerts →

Market Data

Market Cap$6.70B
Shares Outstanding83.15M
Float55.05M
Cash$124.48M
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↑ 21.8% shares (2026Q1 vs prior)
262 institutional holders · 111.69M shares
#1 Avoro Capital Advisors LLC 14.95M shares
#2 FMR LLC 11.70M shares
#3 BAKER BROS. ADVISORS LP 8.66M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest9.98M
Days to Cover18.1
% of Float18.1%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2020-12-31
4 INSIDER TRANSACTION 2026-04-29
4 INSIDER TRANSACTION 2026-04-24
4 INSIDER TRANSACTION 2026-04-24
4 INSIDER TRANSACTION 2026-04-16
Full SEC filing analysis available with free account

Recent News

No recent news

Factual KYMR Dilution Snapshot

Kymera Therapeutics, Inc. (KYMR) has a DilutionScore of 50/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track KYMR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking KYMR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for KYMR
KYMR FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.